Cantor Fitzgerald

WebsiteDirections Contact us

$15.00
OFF

Cantor Fitzgerald Boosts Rigel Pharmaceuticals (NASDAQ:RIGL) …

1 week from now

Dec 13, 2024 · Rigel Pharmaceuticals (NASDAQ:RIGL – Free Report) had its target price hoisted by Cantor Fitzgerald from $15.00 to $25.00 in a report published on Tuesday,Benzinga …

americanbankingnews.com

$15.00
OFF

Cantor Fitzgerald Issues Positive Forecast For Rigel Pharmaceuticals ...

1 week from now

Dec 11, 2024 · Rigel Pharmaceuticals (NASDAQ:RIGL – Free Report) had its target price lifted by Cantor Fitzgerald from $15.00 to $25.00 in a research report released on Tuesday …

etfdailynews.com

$15.00
OFF

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Pass Above 200

1 week from now

Dec 26, 2024 · Cantor Fitzgerald boosted their target price on Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a "neutral" rating in a research note on Tuesday, December …

marketbeat.com

$25
OFF

Rigel Pharmaceuticals Price Target Raised To $25 From $15 At …

1 week from now

Dec 10, 2024 · Cantor Fitzgerald raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $25 from $15 and keeps a Neutral rating on the shares. Rigel announced initial data from the …

nasdaq.com

$15.00
OFF

RIGL Stock Price Target | Rigel Pharmaceuticals Analyst Ratings

1 week from now

Cantor Fitzgerald: Boost Target: Neutral Neutral: $15.00 $25.00: i. 12/10/2024: HC Wainwright: Reiterated Rating: Buy Buy: $57.00 $57.00: i. 12/6/2024: ... Rigel Pharmaceuticals, Inc. …

pricetargets.com

$25.00
OFF

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock, Analyst Ratings, Price ...

1 week from now

The latest price target for Rigel Pharmaceuticals (NASDAQ:RIGL) was reported by Cantor Fitzgerald on December 10, 2024. The analyst firm set a price target for $25.00 expecting …

benzinga.com

$15.00
OFF

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives ... - MarketBeat

1 week from now

Jan 3, 2025 · Cantor Fitzgerald increased their price target on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a "neutral" rating in a research report on …

marketbeat.com

$15
OFF

Cantor Fitzgerald Maintains Neutral On Rigel Pharmaceuticals, …

1 week from now

Dec 10, 2024 · Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $15 to $25.

sahmcapital.com

$15
OFF

Cantor Fitzgerald Reiterates Neutral On Rigel Pharmaceuticals ...

1 week from now

Sep 20, 2024 · Cantor Fitzgerald analyst Kristen Kluska reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and maintains $15 price target.

sahmcapital.com

$2.00
OFF

Cantor Fitzgerald Raises Rigel Pharmaceuticals (NASDAQ:RIGL) …

1 week from now

Mar 7, 2024 · Rigel Pharmaceuticals (NASDAQ:RIGL – Free Report) had its price objective increased by Cantor Fitzgerald from $2.00 to $3.00 in a research note published on …

americanbankingnews.com

$25.00
OFF

Cantor Fitzgerald Remains A Hold On Rigel (RIGL)

1 week from now

Dec 10, 2024 · In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Hold rating on Rigel (RIGL – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

$0.06
OFF

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

1 week from now

Jan 10, 2025 · Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.06) earnings per …

marketbeat.com

$3
OFF

Cantor Fitzgerald Maintains Neutral On Rigel Pharmaceuticals, …

1 week from now

Jun 3, 2024 · Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $3. Benzinga·03/06/2024 17:34:17. Listen to the news. Cantor Fitzgerald analyst Kristen …

webull.com.sg

$36.20
OFF

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 …

1 week from now

Jan 6, 2025 · Finally, Cantor Fitzgerald lifted their price target on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, …

defenseworld.net

FAQs about Cantor Fitzgerald Coupon?

What is the forecast for Rigel Pharmaceuticals stock?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Rigel Pharmaceuticals is $36.20, with a high forecast of $57.00 and a low forecast of $23.00. Should I buy or sell Rigel Pharmaceuticals stock right now? ...

Should you buy Rigel Pharmaceuticals stock?

The consensus among Wall Street research analysts is that investors should "hold" RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares. Does Rigel Pharmaceuticals's stock price have much upside? ...

What is the price target for Rigel Pharmaceuticals (Rigl)?

The highest price target for RIGL is $57.00, while the lowest price target for RIGL is $23.00. The average price target represents a forecasted upside of 76.07% from the current price of $20.56. Enter your email address to receive the latest news and analysts' ratings for Rigel Pharmaceuticals and its competitors. DeFi Coin on Verge of Breakout! ...

Should you buy Rigel (Rigel)?

Currently, the analyst consensus on Rigel is a Moderate Buy with an average price target of $34.80, a 53.10% upside from current levels. In a report released today, B.Riley Financial also maintained a Hold rating on the stock with a $20.00 price target. ...

What was Rigel Pharmaceuticals' stock price in 2024?

Rigel Pharmaceuticals' stock was trading at $14.50 at the beginning of 2024. Since then, RIGL stock has increased by 13.8% and is now trading at $16.50. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings results on Tuesday, August, 6th. ...

What does Rigel Pharmaceuticals do?

Rigel (RIGL) Company Description: Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. ...